Medical decisions regarding hormone therapy for menopausal women are significantly influenced by the media

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 1, 2007, Pages 28-31

  Archer, David F ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; HORMONE DERIVATIVE; PLACEBO;

BEHAVIOR CHANGE; BREAST CANCER; CLINICAL TRIAL; ENDOMETRIUM CANCER; EXERCISE; FOOD INTAKE; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; INFORMATION DISSEMINATION; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; LIFESTYLE; MASS MEDIUM; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MENOPAUSAL SYNDROME; MENOPAUSE; NOTE; OSTEOPOROSIS; PATIENT COUNSELING; PEER REVIEW; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; WOMEN'S HEALTH;

DECISION MAKING; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MASS MEDIA; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 33846520547     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1342     Document Type: Note

References (29)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321-333.
2. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349(6): 523-534.
3. Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976; 294(23): 1262-1267.
4. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975; 293(23): 1164-1167.
5. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975; 293(23): 1167-1170.
6. Jick H, Watkins RN, Hunter JR, et al. Replacement estrogens and endometrial cancer. N Engl J Med 1979; 300(5): 218-222.
7. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993; 153(19): 2209-2216.
8. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75(6): 1102-1109.
9. Bush TL, Fried LP, Barrett-Connor E. Cholesterol, lipoproteins. and coronary heart disease in women. Clin Chem 1988; 34(8B): B60-B70.
10. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133(12): 933-941.
11. Grodstein F, Stampfer MJ, Falkeborn M, Naessen T, Persson I. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology 1999; 10(5): 476-480.
12. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335(7): 453-461.
13. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991; 325(11): 756-762.
14. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 55-72.
15. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288(1): 49-57.
16. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280(7): 605-613.
17. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291(14): 1701-1712.
18. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005; 162(5): 404-414.
19. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006; 166(7): 772-780.
20. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292(13): 1573-1580.
21. Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001; 98(3): 498-508.
22. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003; 289(24): 3243-3253.
23. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006.
24. Cui Y, Whiteman MK, Flaws JA, Langenberg P, Tkaczuk KH. Bush TL. Body mass and stage of breast cancer at diagnosis. Int J Cancer 2002; 98(2): 279-283.
25. Guay MP, Dragomir A, Pilon D, Moride Y, Perreault S. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. PD Safe 2006.
26. Grady D, Ettinger B, Tosteson AN, Pressman A, Macer JL. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 2003; 102(6): 1233-1239.
27. Gerend MA, Aiken LS, Erchull MJ, Lapin A. Women's use of hormone therapy before and after the Women's Health Initiative: a psychosocial model of stability and change. Prev Med 2006.
28. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause 2004; 11(6 Pt 1): 589-600.
29. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006; 15(1): 35-44.